Data / Drug companies / Florida Pharmaceutical Products, LLC
Florida Pharmaceutical Products, LLC: 44 products in the FDA NDC directory, labeler code 71921
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Florida Pharmaceutical Products, LLC (labeler code 71921) lists 44 products in the FDA National Drug Code Directory, covering 25 finished drugs by generic name. By type: 44 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on April 14, 2026.
The request: Watch Florida Pharmaceutical Products, LLC (FDA labeler code 71921): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 71921
- Products in commercial distribution
- 44
- Packages
- 66
- Finished drugs by generic name
- 25
- Prescription products
- 44
- Over the counter products
- 0
- Controlled substance products
- Schedule V 6
- Flagged as original packager
- 43 of 43 products that carry the flag
- Started marketing in the last 12 months
- 12
- Earliest marketing start
- January 15, 2021
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 43 | 97.7% |
| New drug applications (NDA) | 1 | 2.3% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 44 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Doxepin hydrochloride | 5 | 45 |
| Lacosamide | 4 | 57 |
| Ibuprofen | 3 | 190 |
| Glimepiride | 3 | 32 |
| Allopurinol | 3 | 54 |
| Varenicline tartrate | 3 | 23 |
| Abiraterone acetate | 2 | 22 |
| Glycopyrrolate | 2 | 64 |
| Dapagliflozin | 2 | 26 |
| Rasagiline mesylate | 2 | 6 |
| Tenofovir disoproxil fumarate | 1 | 16 |
| Rivaroxaban | 1 | 24 |
| Brimonidine tartrate | 1 | 15 |
| Lofexidine | 1 | 3 |
| Brivaracetam oral | 1 | 1 |
| Dorzolamide hydrochloride ophthalmic | 1 | 1 |
| Brimonidine tartrate and timolol maleate | 1 | 14 |
| Dorzolamide hydrochloride timolol maleate | 1 | 1 |
| Sumatriptan | 1 | 28 |
| Exemestane | 1 | 12 |
| Aminocaproic acid | 1 | 23 |
| Valganciclovir | 1 | 14 |
| Lacosamide oral | 1 | 1 |
| Acyclovir | 1 | 70 |
| Mercaptopurine | 1 | 4 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 19 | 43.2% |
| Tablet, film coated | 7 | 15.9% |
| Capsule | 6 | 13.6% |
| Solution | 5 | 11.4% |
| Tablet, coated | 2 | 4.5% |
| Solution/ drops | 2 | 4.5% |
| Kit | 1 | 2.3% |
| Spray | 1 | 2.3% |
| Powder, for solution | 1 | 2.3% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Rasagiline mesylate | 71921-408 | Tablet | Generic drugs (ANDA) | April 14, 2026 |
| Rasagiline mesylate | 71921-407 | Tablet | Generic drugs (ANDA) | April 14, 2026 |
| Dapagliflozin | 71921-421 | Tablet | Generic drugs (ANDA) | April 6, 2026 |
| Dapagliflozin | 71921-420 | Tablet | Generic drugs (ANDA) | April 6, 2026 |
| Brivaracetam oral Solution | 71921-410 | Solution | Generic drugs (ANDA) | February 24, 2026 |
| Acyclovir | 71921-146 | Capsule | Generic drugs (ANDA) | February 18, 2026 |
| Glycopyrrolate | 71921-111 | Tablet | Generic drugs (ANDA) | February 12, 2026 |
| Glycopyrrolate | 71921-110 | Tablet | Generic drugs (ANDA) | February 12, 2026 |
| Lacosamide Oral Solution | 71921-411 | Solution | Generic drugs (ANDA) | January 30, 2026 |
| Mercaptopurine | 71921-150 | Tablet | New drug applications (NDA) | January 30, 2026 |
| Aminocaproic Acid | 71921-175 | Solution | Generic drugs (ANDA) | December 20, 2025 |
| Tenofovir Disoproxil Fumarate | 71921-105 | Tablet, coated | Generic drugs (ANDA) | November 26, 2025 |
| Rivaroxaban | 71921-405 | Tablet | Generic drugs (ANDA) | August 20, 2025 |
| Allopurinol | 71921-241 | Tablet | Generic drugs (ANDA) | May 22, 2025 |
| Dorzolamide Hydrochloride Ophthalmic | 71921-400 | Solution | Generic drugs (ANDA) | May 7, 2025 |
| Varenicline tartrate | 71921-309 | Tablet, film coated | Generic drugs (ANDA) | November 1, 2024 |
| Varenicline tartrate | 71921-308 | Tablet, film coated | Generic drugs (ANDA) | November 1, 2024 |
| Varenicline | 71921-307 | Kit | Generic drugs (ANDA) | November 1, 2024 |
| Lofexidine | 71921-250 | Tablet, coated | Generic drugs (ANDA) | August 21, 2024 |
| Brimonidine tartrate and timolol maleate | 71921-188 | Solution | Generic drugs (ANDA) | November 23, 2023 |
| Allopurinol | 71921-242 | Tablet | Generic drugs (ANDA) | October 31, 2023 |
| Allopurinol | 71921-240 | Tablet | Generic drugs (ANDA) | October 31, 2023 |
| Lacosamide | 71921-223 | Tablet | Generic drugs (ANDA) | September 21, 2023 |
| Lacosamide | 71921-222 | Tablet | Generic drugs (ANDA) | September 21, 2023 |
| Lacosamide | 71921-221 | Tablet | Generic drugs (ANDA) | September 21, 2023 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.